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OBJECTIVEdTo estimate the prevalence of and risk factors for diabetic peripheral neurop-
athy (DPN) in a pilot study among youth participating in the SEARCH for Diabetes in Youth
study.
RESEARCH DESIGN AND METHODSdDPN was assessed using the Michigan
Neuropathy Screening Instrument (MNSI) (examination for foot abnormalities, distal
vibration perception, and ankle reflexes). An MNSI exam (MNSIE) score .2 is diagnostic
for DPN.
RESULTSdThe MNSIE was completed in 399 subjects, including 329 youth with type 1
diabetes (mean age 15.7 6 4.3 years, duration 6.2 6 0.9 years) and 70 with type 2 diabetes
(mean age 21.66 4.1 years, duration 7.66 1.8 years). Glycated hemoglobin (A1C) was similar
in both groups (8.8 6 1.8% for type 1 vs. 8.5 6 2.9% for type 2). The prevalence of DPN was
significantly higher in youth with type 2 compared with those with type 1 diabetes (25.7 vs.
8.2%; P, 0.0001). In unadjusted analyses, diabetes type, older age, longer duration of diabetes,
increased waist circumference, elevated blood pressure, lower HDL cholesterol, and presence of
microalbuminuria (urinary albumin-to-creatinine ratio .30 mg/g) were associated with DPN.
The association between diabetes type andDPN remained significant after adjustment for age and
sex (odds ratio 2.29 [95% CI 1.05–5.02], P = 0.03).
CONCLUSIONSdDPN prevalence among youth with type 2 diabetes approached
rates reported in adult populations with diabetes. Our findings suggest not only that
youth with diabetes are at risk for DPN but also that many already show measurable signs
of DPN.
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The incidence of both type 1 and type2 diabetes in youth is increasingworldwide (1,2). Recent reports
have projected that, if this trend contin-
ues, the prevalence of diabetes among the
young in the U.S. could triple by the year
2050 (3). This could incur a significant
burden on health care costs and on soci-
ety, especially as these young people enter
their peak working and earning capacity
at the time when diabetes complications
begin to occur. Diabetic peripheral neu-
ropathy (DPN) is among the most dis-
tressing of all the chronic complications
of diabetes and is a cause of significant
disability and poor quality of life (4). De-
pending on the patient population and
diagnostic criteria, the prevalence of
DPN among adults with diabetes ranges
from 30 to 70% (5–7). However, there are
insufficient data on the prevalence and
predictors of DPN among the pediatric
population. Furthermore, early detection
and good glycemic control have been
proven to prevent or delay adverse out-
comes associated with DPN (5,8,9). Near-
normal control of blood glucose beginning
as soon as possible after the onset of diabe-
tes may delay the development of clinically
significant nerve impairment (8,9). There-
fore, children and adolescents with diabe-
tes represent a critical target for primary
prevention of this complication.
The American Diabetes Association
(ADA) recommends screening for DPN in
children and adolescents with type 2
diabetes at diagnosis and 5 years after
diagnosis for those with type 1 diabetes,
followed by annual evaluations thereafter,
using simple clinical tests (10). Since sub-
clinical signs of DPN may precede devel-
opment of frank neuropathic symptoms,
systematic, preemptive screening is re-
quired in order to identify DPN in its ear-
liest stages.
There are various measures that can
be used for the assessment of DPN. The
Michigan Neuropathy Screening Instru-
ment (MNSI) is a simple, sensitive, and
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specific tool for the screening of DPN
(11). It was validated in large indepen-
dent cohorts (12,13) and has been widely
used in clinical trials and longitudinal co-
hort studies including the Diabetes Control
and Complications Trial/Epidemiology of
Diabetes Interventions and Complications
(DCCT/EDIC) (13).
The aim of this pilot study was to
provide preliminary estimates of the prev-
alence of and factors associated with DPN
among children and adolescents with
type 1 and type 2 diabetes.
RESEARCH DESIGN AND
METHODS
Study participants and data
collection
SEARCH for Diabetes in Youth is a
population-based studyof diabetes in young
people of diverse racial and ethnic back-
grounds in the U.S. (14). Study methods
for SEARCH have previously been de-
scribed (14). SEARCH is an observational
longitudinal study of youth with diabetes
diagnosed before the age of 20 years in
the U.S. SEARCH participants are drawn
from four geographically defined popula-
tions in Ohio, Washington, South Caro-
lina, and Colorado; health plan enrollees
in Hawaii and California; and Indian
Health Service beneficiaries from four
American Indian populations. Prior to
protocol implementation, local institu-
tional review board approval was ob-
tained for each center. Participants 18
years and older and parents of youth un-
der age 18 years provided written in-
formed consent for participation; youth
provided assent.
Once enrolled, the parent/guardian
or study participants age 18 years and
older were invited to complete a short
survey that included questions about race
and ethnicity, diabetes treatment, and
other information. Participants who
completed the initial survey were invited
to a baseline study visit; surveys were
administered to obtain clinical and de-
mographic information, as well as psy-
chosocial burden. In addition, a physical
examination was completed to measure
systolic and diastolic blood pressure,
height, weight, and waist circumfer-
ence. A blood sample was collected by
venipuncture. Youth whose diabetes
was incident in 2002 through 2005
and who completed a baseline study
visit were invited to return for follow-
up visits at ~12, 24, and 60 months after
their baseline visit. Youth who missed a
follow-up visit window remained eligible
to complete the subsequent follow-up
visit(s).
Data for this pilot study were col-
lected from five of the SEARCH sites and
included 399 youth diagnosed with di-
abetes before 20 years of age whose di-
abetes was incident in 2002–2005. DPN
assessment was conducted at the 60-
month follow-up visit. In addition, a sub-
set of youth with type 2 diabetes who
were part of the 2001 prevalent cohort
that participated in a baseline visit were
also invited to participate in the DPN
pilot study. The pilot study was approved
by the institutional review board(s) at
each study site. Diabetes type was cate-
gorized as type 1 or type 2 based on
the health care provider diagnosis. Race/
ethnicity was self-reported using
the 2000 census questionnaire format,
and five categories were created: non-
Hispanic white, Hispanic (regardless of
race), non-Hispanic black, Asian/Pacific
Islander, and Native American. Current
cigarette smoking was defined as having
smoked cigarettes on $1 of the 30 days
preceding the survey. Blood samples
were obtained under conditions of
metabolic stability after at least 8 h of fast-
ing. Specimens were processed locally at
the sites and shipped within 24 h to the
central laboratory (Northwest Lipid
Metabolism and Diabetes Research Lab-
oratories, University of Washington),
where they were analyzed for measure-
ment of total cholesterol, HDL choles-
terol, LDL cholesterol, triglycerides, and
glycated hemoglobin (A1C) as previ-
ously described (14). Urinary albumin
levels were assessed on a random spot
urine sample, and microalbuminuria
was defined as urine albumin-to-
creatinine ratio .30 mg albumin/g
creatinine.
Assessment of DPN
DPN was assessed using the MNSI, a vali-
dated screening tool (11). SEARCH staff
from each center were centrally trained
and certified to perform the MNSI. The
MNSI is a 15-item self-administered ques-
tionnaire (MNSIQ) and structured exami-
nation of the feet (MNSIE) scored for
abnormalities of appearance (deformities,
infection, and dry skin/callus), presence
of ulcers, vibration perception threshold
(VPT) at the distal great toe, and ankle re-
flexes. Threshold for DPN, established by
prior validation studies performed among
adults, is a score of .2 on the MNSIE
(12,13).
Statistical analyses
Differences in the demographic, anthro-
pometric, clinical, and metabolic param-
eters between adolescents and young
adults with type 1 and type 2 diabetes
were compared using Student t test for
continuous variables and the x2 test for
categorical variables. Factors associated
with DPN were assessed independently
using the cutoff score of 2 on the MNSIE
to define DPN. Logistic regression analy-
sis was conducted to estimate the odds of
DPN associated with diabetes type, con-
trolling for the variables found to be sig-
nificant in the univariate analysis. The
data were analyzed using SAS 9.2 (SAS
Institute, Cary, NC). The level of signifi-
cance was set at a = 0.05.
RESULTSdThe characteristics of the
study population are depicted in Table 1.
A total of 399 youth (329 with type 1 and
70 with type 2 diabetes) participated in
the pilot study. Youth with type 1 diabe-
tes were younger (mean age 15.7 6 4.3
years) and had a shorter duration of di-
abetes (mean duration 6.2 6 0.9 years)
compared with youth with type 2 diabe-
tes (mean age 21.66 4.1 years and mean
duration 7.6 6 1.8 years). Participants
with type 2 diabetes had a higher BMI z
score and waist circumference, were more
likely to be smokers, and had higher
blood pressure and lipid levels than youth
with type 1 diabetes (all P, 0.001). A1C,
however, did not significantly differ be-
tween the two groups (mean A1C 8.8 6
1.8% [73 6 2 mmol/mol] for type 1 di-
abetes and 8.5 6 2.9% [72 6 3 mmol/
mol] for type 2 diabetes; P = 0.5) but was
higher than that recommended by the
ADA for this age-group (A1C #7.5%)
(10). The prevalence of DPN (defined as
the MNSIE score .2) was 8.2% among
youth with type 1 diabetes and 25.7%
among those with type 2 diabetes.
Unadjusted associations between de-
mographic, anthropometric, and meta-
bolic parameters and DPN are presented
in Table 2. Youth with DPN were older
and had a longer duration of diabetes,
greater central obesity (increased waist
circumference), higher blood pressure,
an atherogenic lipid profile (low HDL
cholesterol and marginally high triglycer-
ides), and microalbuminuria. A1C, al-
though above that recommended by
ADA for optimal glycemic control among
youth, was not significantly different be-
tween those with and without DPN
(9.0% 6 2.0 or 75.0 6 2 0.0 mmol/mol
vs. 8.8%6 2.1 or 72.06 2.0 mmol/mol,
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P = 0.58). Although nearly 37%of youthwith
type 2 diabetes came from lower-income
families with annual income ,25,000
USD per annum (as opposed to 11%
for type 1 diabetes), socioeconomic sta-
tus was not significantly associated with
DPN (P = 0.77).
In the unadjusted logistic regression
model, the odds of having DPN was
nearly four times higher among those
with type 2 diabetes compared with
youth with type 1 diabetes (odds ratio
[OR] 3.8 [95% CI 1.9–7.5, P , 0.0001).
This association was attenuated, but re-
mained significant, after adjustment for
age and sex (OR 2.3 [95% CI 1.1–5.0],
P = 0.03). However, this association was
no longer significant (OR 2.1 [95% CI
0.3–15.9], P = 0.47) when additional co-
variates, significant in the univariate
analyses (age, diabetes duration, waist cir-
cumference, blood pressure, HDL choles-
terol, and microalbuminuria), were
added to the model (Table 3).
CONCLUSIONSdIn a pilot study of a
multiethnic cohort of youth with diabe-
tes, the prevalence of DPN was 8.2%
among youth with type 1 diabetes and
25.7% among those with type 2 diabetes.
Youth with DPN were more likely to have
type 2 diabetes and an adverse cardiovas-
cular risk profile (central obesity, higher
blood pressure, and lower HDL) and
microalbuminuria. The prevalence of
DPN among type 1 diabetes youth in
our pilot study is lower than that reported
by Eppens et al. (15) among 1,433 Aus-
tralian adolescents with type 1 diabetes
assessed by thermal threshold testing
and VPT (prevalence of DPN 27%; me-
dian age and duration 15.7 and 6.8 years,
respectively). A much higher prevalence
was also reported among Danish (62.5%)
and Brazilian (46%) cohorts of type 1 di-
abetes youth (16,17) despite a younger
age (mean age among Danish children
13.7 years and Brazilian cohort 12.9
years). The prevalence of DPN among
youth with type 2 diabetes (26%) found
in our study is comparable to that re-
ported among the Australian cohort (21%)
(15). The wide ranges in the prevalence
estimates of DPN among the young cannot
solely be attributed to the inherent racial/
ethnic differences in this population but
could potentially be due to the differ-
ing criteria and diagnostic tests used
to define and characterize DPN. The
Australian cohort used thermal and VPT
to assess DPN, while the Danish cohort
used VPT only.
Metabolic syndrome components
such as central obesity, elevated blood
pressure, and dyslipidemia have been
implicated in the pathogenesis of DPN.
In the EURODIAB study which prospec-
tively followed 1,172 subjects with type 1
diabetes for 7.3 years (mean age 306 8.8
years, A1C 8.0 6 1.8%, and duration
12 6 8 years) the authors reported that,
apart from glycemic control, the inci-
dence of DPN was significantly associated
with potentially modifiable cardiovas-
cular risk factors, including raised tri-
glyceride levels, BMI, smoking, and
hypertension (18). In the population-
basedMonitoring of Trends and Determi-
nants inCardiovascularDisease (MONICA)/
Cooperative Health Research in the Region
of Augsburg (KORA) study, DPN assessed
by MNSI was associated with increasing
age and abdominal obesity (19). The
Pittsburgh Epidemiology of Diabetes
Complications Study (EDC) has estab-
lished that low HDL cholesterol is associ-
ated with prevalent polyneuropathy (20)
and that hypertension and smoking are
predictors of incident polyneuropathy
(21). These data thus support the rela-
tionship between DPN and cardiovascu-
lar risk factors (central obesity, lower
HDL, and elevated blood pressure) found
in our study, although in a much younger
cohort.
In our study, the duration of diabetes
was significantly longer among those with
DPN, but A1C values did not differ
significantly between the two groups,
suggesting that a longer duration with
its sustained impact on peripheral nerves
is an important determinant of DPN.
Table 1dCharacteristics of the study population by diabetes status: the SEARCH for
Diabetes in Youth DPN pilot study
Participant characteristics Type 1 Type 2 P
N 329 70
Age (years) 15.7 (4.4) 21.6 (4.2) ,0.0001
Female, n (%) 168 (51.0) 42 (60.0) 0.18
Diabetes duration (years) 6.2 (0.9) 7.6 (1.8) ,0.0001
Race/ethnicity, n (%) ,0.0001
Non-Hispanic white 261 (79.3) 20 (28.5)
Non-Hispanic black 39 (11.8) 27 (38.5)
Hispanic 27 (8.2) 17 (24.2)
Asian/Pacific Islander 1 (0.3) 4 (5.7)
Native American 0 (0.0) 1 (1.4)
Other 1 (0.3) 1 (1.4)
Income (USD), n (%) ,0.0001
,25,000 34 (11.0) 14 (36.8)
25,000–49,000 57 (18.4) 6 (15.7)
50,000–74,000 52 (16.8) 1 (2.6)
$75,000 127 (41.1) 2 (5.2)
DK/Ref 39 (12.6) 15 (39.4)
A1C 0.52
% 8.83 (1.8) 8.50 (2.9)
mmol/mol 73 (2) 72 (3)
BMI z score 0.58 (0.8) 1.83 (0.8) ,0.0001
Insulin treated, n (%) 307 (99.3) 15 (51.7) ,0.0001
Current smoker, n (%) 40 (14.3) 14 (37.8) 0.0011
Positive MNSI examination, n (%) 27 (8.2) 18 (25.7) ,0.0001
Waist circumference (cm) 80.32 (15.7) 114.30 (30.1) ,0.0001
DBP (mmHg) 62.59 (10.20) 74.10 (11.1) ,0.0001
SBP (mmHg) 100.10 (13.0) 115.80 (14.6) ,0.0001
Urine ACR (mg/g)* 2.47 (9.10) 18.09 (75.7) 0.0016
Microalbuminuria, n (%) 3 (1.1) 5 (7.9) 0.0080
Triglycerides (mg/dL)* 91.10 (72.9) 177.1 (204.1) ,0.0001
HDL (mg/dL) 57.37 (14.5) 41.40 (10.0) ,0.0001
LDL (mg/dL) 95.22 (26.3) 107.80 (31.7) 0.0036
Data are means (SD) unless otherwise indicated. Microalbuminuria = albumin-to-creatinine ratio (ACR).30
mg/g. DBP, diastolic blood pressure; DK/Ref, do not know/refused to answer; SBP, systolic blood pressure.
*Using log distribution for association tests.
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However, the A1C was above that recom-
mended by ADA for optimal glycemic
control among both youth with and youth
without DPN. Cho et al. (22) reported
an increase in the prevalence of DPN
from 14 to 28% over 17 years among
819 Australian adolescents with type 1 di-
abetes aged 11–17 years at baseline, despite
improvements in care and minor im-
provements in A1C (8.2–8.7%). The pro-
spective Danish Study Group of Diabetes
in Childhood also found no association be-
tween DPN (assessed by VPT) and glycemic
control (23).
Nerve conduction studies are still
regarded as the gold standard measure
to assess DPN, but the discomfort associ-
ated with the procedure and significant
investment in time, personnel training,
and costs preclude their use in routine
clinical practice. Assessment using the
MNSI, however, is noninvasive and easy
to use in large, multicenter cohorts and in
adults was shown to be specific (95%)
and sensitive (80%) for identifying the
presence of DPN, with a positive pre-
dictive value of 97% and a negative pre-
dictive value of 74% (11,13).
The ADA recommends that health care
providers perform an annual compre-
hensive foot examination for all patients
with diabetes to identify neuropathy risk
factors predictive of ulcers and ampu-
tations (24). This examination should
include inspection, assessment of foot
pulses, and testing for loss of protective
sensation (10-g monofi lament plus
testing any one of the following: vibra-
tion using 128-Hz tuning fork, pinprick
sensation, ankle reflexes, or VPT).
The MNSI incorporates most of these
tests recommended by the ADA and is
thus an ideal bedside screening tool
for DPN.
Our study has limitations that must
be taken into consideration. The results of
this study should be interpreted cau-
tiously, as the MNSI has not been vali-
dated in children and adolescents,
although several of its components (vi-
bration perception using 128-Hz tuning
fork, pinprick sensation, and ankle re-
flexes) have been used among the pediat-
ric population for DPN screening. The
cross-sectional design of the study and
the lack of information on prior A1C data
could be a reason for the lack of associ-
ation between DPN and A1C, as we could
not include a weighted A1C over time
into the model. The loss of the association
between diabetes type and DPN with
addition of covariates in the fully adjusted
model could be due to power loss, given
the small number of youth with DPN in
the sample, or indicative of stronger
associations between these covariates
and DPN such that conditioning on
them eliminates the observed association
between DPN and diabetes type. More
data are needed to further characterize the
relationship between DPN and diabetes
type in youth. While the data presented
come from a pilot study conducted in
2009–2010, the SEARCH cohort study is
currently collecting data on DPN in an
estimated sample of 3,000 youth with
type 1 and type 2 diabetes, which will
have more power and allow a more com-
prehensive evaluation of prevalence of
and risk factors for the development and
progression of DPN.
In conclusion, our pilot study found
evidence that the prevalence of DPN in
adolescents with type 2 diabetes ap-
proaches rates reported in adults with
diabetes. Several CVD risk factors such as
central obesity, elevated blood pressure,
dyslipidemia, and microalbuminuria,
previously identified as predictors of
DPN among adults with diabetes,
emerged as independent predictors of
DPN in this young cohort and likely
accounted for the increased prevalence of
DPN in youth with type 2 diabetes.
Awareness and periodic assessment of
this complication in its early subclinical
stage might prevent the poor quality of life
associated with DPN in the future by
Table 2dDifferences in the demographic, anthropometric, and metabolic parameters
between youth with and youth without DPN: the SEARCH for Diabetes in Youth DPN pilot
study
Variable DPN+ (MNSIE .2) DPN2 (MNSIE #2) P
N 45 354
Age (years) 17.91 (4.07) 16.11 (4.43) ,0.0001
Female, n (%) 23 (51.11) 187 (51.09) 0.87
Diabetes duration (years)* 7.0 (1.4) 6.3 (1.7) 0.0002
Diabetes type ,0.0001
Type 1, n (%) 27 (60.00) 302 (85.31)
Type 2, n (%) 18 (40.00) 52 (14.69)
Race/ethnicity, n (%) 0.65
Non-Hispanic white 28 (62.22) 253 (71.47)
Non-Hispanic black 10 (22.22) 56 (15.82)
Hispanic 6 (13.33) 38 (10.57)
Asian/Pacific Islander 1 (2.22) 4 (1.13)
Native American 0 (0.00) 1 (0.28)
Other 0 (0.00) 2 (0.56)
Income (USD), n (%) 0.77
,25,000 6 (19.35) 42 (13.29)
25,000–49,000 6 (19.35) 57 (18.04)
50,000–74,000 4 (12.90) 49 (15.51)
$75,000 9 (29.03) 120 (37.97)
DK/Ref 6 (19.35) 48 (15.19)
A1C 0.58
% 9.01 (2.04) 8.77 (2.05)
mmol/mol 75 (2) 72 (2)
BMI z score 0.48 (1.50) 0.74 (0.90) 0.15
Current smoker, n (%) 8 (17.7) 46 (12.5) 0.19
Waist circumference (cm) 103.31 (42.21) 84.04 (18.21) ,0.0001
DBP (mmHg) 72.09 (12.66) 63.64 (10.71) ,0.0001
SBP (mmHg) 110.46 (17.48) 101.90 (13.92) ,0.0001
Urine ACR (mg/g)* 9.76 (23.82) 4.98 (36.06) 0.0019
Microalbuminuria, n (%) 2 (5.56) 6 (2.18) 0.2339
Triglycerides (mg/dL)* 116.84 (78.45) 107.96 (122.74) 0.07
HDL (mg/dL) 48.28 (14.33) 54.82 (15.15) 0.01
LDL (mg/dL) 96.08 (26.88) 98.07 (28.17) 0.6
Data are means (SD) unless otherwise indicated. Microalbuminuria = albumin-to-creatinine ratio (ACR).30
mg/g. DBP, diastolic blood pressure; DK/Ref, do not know/refused to answer; SBP, systolic blood pressure.
*Using log distribution for association tests.
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allowing early application of suitable in-
terventions. Further long-term study of
DPN in youth is needed.
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